Recalcitrant DME was defined as persistent macular edema with CFT [greater than or equal to]300 [micro]m, lasting 3 months after at least 3 intravitreal anti-VEGF and 3 IVTA
injections with 2 sessions of focal grid laser photocoagulation.
For Pseudophakic eyes, IVTA
or dexamethasone implant with or without laser may also be considered.
In conclusion, IVTA
remains a promising therapy for patients with macular oedema of different aetiologies refractory to other modalities of treatment at least in short terms.
There were 11 patients in IVBe group (55%), and 9 patients in IVTA
is a promising treatment for DME12 but inexicably linked to elevation of intraocular pressure13 retinal detachment glaucoma ocular hypertone intraocular hemorrhage endophthalmitis14 and Subtenon triamcinolone.
While Figure 3 represents the first phase of the project, the IVTA
partnership is more ambitious than that.
RESULTS AND OBSERVATIONS: Out of the total 42 patients, 1 patient receiving 1-mg of IVTA
and 1 patient receiving 4-mg of IVTA
were lost to follow up.
In patients with diabetic macular oedema not responsive to photocoagulation, either IVTA
or an intravitreal anti-VEGF agent may be considered as second-line treatments.
in suspension form is currently available as the following commercial preparations: Trivaris (Allergan, Irvine, CA, USA), Kenacort (Bristol-Myers-Squibb, Melbourne, Australia) and Kenalog (Bristol-Myers-Squibb, Princeton, NY, USA).
It was not statistically significant to say that IVTA
sonrasi GIB artisi gelisimi farkli calismalarda farkli oranlarda bildirilmektedir.
Calismamizin amaci IVTA
uygulamasinin OCT ile tespit edilen DMO alt tipleri uzerindeki etkinliginin farklilik gosterip gostermedigini arastirmaktir.